Latest revenue
$0
as of 2025-09-30
Latest net income
$-26.7M
as of 2025-09-30
Net margin
—
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $289.0M
- Enterprise value
- $289.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $6.95
- 52-wk low
- $1.13
- Beta
- —
- Shares out
- 71.2M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an…
AI summary unavailable — showing raw filing excerpt
Generated from ZNTL's filing dated 2026-03-26
Key risks
Item 1A. Risk Factors You should carefully consider the risks and uncertainties described below and the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your…
AI summary unavailable — showing raw filing excerpt
Generated from ZNTL's filing dated 2026-03-26
Profitability
Operating margin
-283.6%
Net margin
-246.0%
Return on equity
-63.4%
28.9%Return on assets
-47.4%
23.1%Leverage
Debt / equity
0.34×
21.8%Debt / assets
25.2%
16.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-35.4M | +26.8% | — |
Q4 2025 2025-12-31 | $0 | -100.0% | $-35.2M | +38.8% | — |
Q3 2025 2025-09-30 | $0 | — | $-26.7M | +33.5% | — |
Q2 2025 2025-06-30 | $0 | — | $-26.9M | +65.6% | — |
Q1 2025 2025-03-31 | $0 | -100.0% | $-48.3M | -579.5% | — |
Q4 2024 2024-12-31 | $26.9M | — | $-57.5M | — | -214.2% |
Q3 2024 2024-09-30 | $0 | — | $-40.2M | +27.7% | — |
Q2 2024 2024-06-30 | $0 | — | $-78.2M | +30.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ZNTL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$7.8M
Insider selling
$10.1M
Net activity
−$2.4M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ZNTL
Institutional value
$27.5M
Total shares held
15.3M
Distinct holders
46
-40 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $5.4M | — | New |
| 2 | Decheng Capital LLC | 1.3M | $3.1M | +0 (+0.0%) | No change |
| 3 | BlackRock, Inc. | 1.3M | $3.0M | +19.9K (+1.6%) | Added |
| 4 | PRIMECAP MANAGEMENT CO/CA/ | 957.4K | $2.2M | +0 (+0.0%) | No change |
| 5 | Pfizer Inc | 953.8K | $2.0M | +0 (+0.0%) | No change |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 792.0K | $1.9M | +4.9K (+0.6%) | Added |
| 7 | JANE STREET GROUP, LLC | 490.3K | $1.1M | +17.2K (+3.6%) | Added |
| 8 | BNP PARIBAS FINANCIAL MARKETS | 471.4K | $1.1M | +52.1K (+12.4%) | Added |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 360.6K | $843.8K | — | New |
| 10 | Peapod Lane Capital LLC | 366.9K | $834.6K | -82.0K (-18.3%) | Trimmed |
| 11 | VANGUARD FIDUCIARY TRUST CO | 304.5K | $712.5K | — | New |
| 12 | Creative Planning | 285.0K | $666.9K | +25.0K (+9.6%) | Added |
| 13 | Anfield Capital Management, LLC | 274.5K | $642.4K | +31.9K (+13.2%) | Added |
| 14 | DIMENSIONAL FUND ADVISORS LP | 272.0K | $634.3K | +175.8K (+182.6%) | Added |
| 15 | SEI INVESTMENTS CO | 191.6K | $448.2K | +24.5K (+14.6%) | Added |
| 16 | UBS Group AG | 155.7K | $364.3K | -518.9K (-76.9%) | Trimmed |
| 17 | Invesco Ltd. | 125.8K | $294.3K | -62.8K (-33.3%) | Trimmed |
| 18 | Hudson Bay Capital Management LP | 117.1K | $274.1K | — | New |
| 19 | BARR E S & CO | 110.0K | $257.4K | +52.5K (+91.3%) | Added |
| 20 | JPMORGAN CHASE & CO | 113.1K | $242.1K | -71.9K (-38.9%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ZNTL's latest filing finishes processing.